Targeted LNP Platform (AIL-111 tLNP)

 

Category: Pharmaceutical

Exhibitor: ACER INCORPORATED

Booth No: M534

 

Characteristic

 

1. Patent-pending core lipid technology
Built on Acer Ionizable Lipid-111（AIL-111）, a proprietary ionizable lipid developed by Acer, the platform provides an expandable foundation for mRNA-LNP delivery.
2. Targeted LNP design
The LNP surface can be functionalized with antibodies or targeting ligands to enable mRNA delivery to selected immune cell populations.
3. T-cell delivery demonstrated across models
In human PBMC ex vivo studies, the platform enabled mRNA delivery to unstimulated CD4⁺ and CD8⁺ T cells while maintaining low background expression in non-target B cells. Mouse studies further showed enhanced mRNA expression in T cells in both spleen and blood, supporting its potential for in vivo immune cell-targeted delivery.
4. Applications in next-generation immune cell engineering
The platform supports potential applications in in vivo CAR-T, T cell engineering, and other cell-specific mRNA therapeutic strategies.

 

Other Products

 

• 

  aiAntigen

• 

  mRNA-AIL-111 LNP platform

 

 

 

Back